The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- Takeda to Conduct Joint Research with Canadian Institute at Shonan Research Center
August 31, 2012
- Eisai Files NDA for Rufinamide for LGS
August 31, 2012
- Novartis to File for COPD Treatment QVA149 in Japan, EU by End of 2012
August 31, 2012
- Kyowa Kirin Temporarily Suspends Patient Enrollment for PIII Study of Its Anticancer Agent ARQ197 Due to ADR
August 31, 2012
- Ribomic Aims to Commercialize Non-Addictive Analgesic Nucleic Acid Drug
August 30, 2012
- Takeda to Start Local Manufacturing at New Russian Factory around FY2014
August 30, 2012
- IBL, IBR to Codevelop Vaccines Using Transgenic Silkworms
August 30, 2012
- Torii to Exclusively Market JT’s Novel Anti-HIV Drug in Japan
August 30, 2012
- GSK Launches ReQuip CR Tablets; MHLW Recommends Use
August 30, 2012
- Takeda Less Dependent on Japan, US Revenues Due to Expanding Emerging Market Biz: CCO Morich
August 29, 2012
- Takeda Gearing Up for Emerging Market Operations
August 29, 2012
- MTPC, Daiichi Sankyo to Launch DPP-4 Inhibitor Tenelia on Sept. 10
August 29, 2012
- Izumo, Former VP of Novartis Institutes for BioMedical Research, Appointed Head of Takeda’s MD Drug Discovery Unit
August 29, 2012
- JT’s Licensee Obtains US Approval for Combination Tablet Containing JTK-303
August 29, 2012
- Nichi-Iko Voluntarily Recalls Lansoprazole OD Tablets 15 mg
August 29, 2012
- Daiichi Sankyo, Eli Lilly Not to Apply for Prasugrel for ACS in the US, Europe
August 29, 2012
- Major US, European Pharmaceutical Makers Faced with “Patent Cliffs”
August 28, 2012
- Plavix Approved for STEMI: sanofi-aventis
August 28, 2012
- Strattera Approved as 1st Adult ADHD Treatment in Japan: Eli Lilly Japan
August 28, 2012
- Growject Approved for SGA Dwarfism: JCR
August 28, 2012
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…